Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.

Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab

Shares have lost roughly half their value since arriving on the Nasdaq in late 2019 via SPAC. Anti-FcRn space is increasingly attractive with 20+ indications on deck or being pursued by leaders Argenx and Janssen.

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Shares of autoimmune disease focused biopharma company Immunovant Inc (US:IMVT) mounted an impressive sharp gain of 107% since the beginning of last week as a wave of news flow sparked a flash of investor confidence that had faded over the course of 2022.

UBS Analyst Gets Immunovant Prediction Horribly Wrong After Stock Price Doubles After Downgrade

The drugmaker announced a $75 million public offering.

Why Immunovant Stock Is Skyrocketing This Week

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF Partners L.P., Commodore Capital, and an undisclosed healthcare specialist fund. Before deducting the underwriting discounts and commissions and offering expenses, the company expects to receive total gross proceeds of $75.0 million. The company intends to use the net proceeds from this offering, together with its existing cash, to accelerate the development of IMVT-1402, including the funding of a proposed pivotal trial. The company expects its existing cash and proceeds from the offering to fund the company into the second half of calendar year 2025. All of the shares are to be sold by the company. The offering is expected to close on or about October 6, 2022, subject to satisfaction of customary closing conditions.

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced a new anti-FcRn, IMVT-1402, at Roivant's Investor Day at 11:00am on September 28, 2022. The presentation can be accessed at the Investor Relations section of the Company's website, located at www.immunovant.com.

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant's Investor Day, taking place on September 28th, 2022.

Immunovant to Present at Roivant Investor Day on September 28th

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12th-14th, 2022.

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced plans to develop batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy and Graves' Disease.

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

Immunovant Announces Two New Development Programs for Batoclimab

Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why

Immunovant, Inc. (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immunovant, Inc. (IMVT) Upgraded to Buy: Here's Why

The consensus price target hints at an 114.4% upside potential for Immunovant, Inc. (IMVT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See an 114% Upside in Immunovant, Inc. (IMVT): Can the Stock Really Move This High?

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoclimab on Wednesday, September 7, 2022 at 8:00 AM ET.

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

Alkermes

Editas Medicine

GlaxoSmithKline

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.

Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug

The mean of analysts' price targets for Immunovant, Inc. (IMVT) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Immunovant, Inc. (IMVT) Could Surge 142%: Read This Before Placing a Bet

Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.

Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab

NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal first quarter ended June 30, 2022.

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report?

Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.

Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development

Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.

Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED

Immunovant, Inc. (NASDAQ:IMVT ) Q4 2022 Earnings Conference Call June 8, 2022 8:00 AM ET Company Participants Pete Salzmann - CEO Conference Call Participants Robyn Karnauskas - Truist Securities Derek Archila - Wells Fargo Thomas Smith - SVB Leerink Douglas Tsao - H.C. Wainwright Operator Good morning.

Immunovant, Inc. (IMVT) CEO Pete Salzmann on Q4 2022 Results - Earnings Call Transcript

Immunovant Inc (NASDAQ: IMVT) has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease (TED).  Immunovant expects to initiate its Phase 3 TED program in 2H of 2022 and is expected.

Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has achieved alignment with the United States Food and Drug Administration (FDA) Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 clinical trials to evaluate batoclimab in TED. Immunovant expects to initiate its Phase 3 TED program in the second half of calendar year 2022.

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022

News for Immunovant Inc Stock (IMVT)